There are 410 resources available
66P - Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster Display session
67P - Blood cell gene expression and clinical characteristics in advanced non-small cell lung cancer with immune-related adverse events
Presenter: Lea Daniello
Session: Poster Display session
69P - The effect of inflammatory-nutritional prognostic scoring system (INPS) on treatment response and prognosis in patients with metastatic NSCLC as second-line treatment with nivolumab
Presenter: Merve Keskinkiliç
Session: Poster Display session
70P - Impact of TP53/KRAS mutations on overall survival of metastatic non-small cell lung cancer patients (pts) treated with systemic first-line therapy
Presenter: Silvia Rubio Novella
Session: Poster Display session
71P - Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Anas Gazzah
Session: Poster Display session
73P - Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)
Presenter: Marcia Horn
Session: Poster Display session
74P - Non-small cell lung cancer (NSCLC) predictors of response to immunotherapy (ICI): LIPI index and immune-related toxicity
Presenter: Alba Moratiel Pellitero
Session: Poster Display session
75TiP - A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)
Presenter: David Planchard
Session: Poster Display session
76TiP - Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in metastatic lung cancer
Presenter: Ismaell Massalha
Session: Poster Display session